Multifunctional role CD36 in progressive renal fibrosis

CD36在进行性肾纤维化中的多功能作用

基本信息

  • 批准号:
    7148352
  • 负责人:
  • 金额:
    $ 12.83万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2006
  • 资助国家:
    美国
  • 起止时间:
    2006-07-01 至 2010-06-30
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): The purpose of this application is to further define key pathways in kidney fibrosis, particularly the functional relationship between ligands and their receptor in the progression of fibrosis. Our preliminary data supports the hypothesis that the scavenger receptor CD36 mediates the proinflammatory and profibrotic effects of thrombospondin and oxidized lipoproteins during progressive renal fibrosis. In response to chronic injury induced by obstruction, CD36 mediates important fibrogenic responses, as the severity of renal fibrosis is significantly attenuated in CD36 deficient mice and is associated with decreased NF-kappa B activation and oxidative stress despite higher levels thrombospondin and nitrotyrosine, a marker of protein oxidation, in the tubulointerstitium. The first aim is to elucidate the profibrotic relationship between CD36 and thrombospondin and oxidized lipoproteins in an animal model of chronic renal fibrosis by: (1) investigating the thrombospondin-CD36 relationship in TGF-beta activation and angiogenesis; and (2) diffentiating oxidant pathways and targets of oxidized protein modification modulated by CD36 through mass spectrometry and 2-D protein gel analysis. The second aim is to differentiate macrophage and renal tubular cell dependent effects of CD36 in fibrogenesis using chimeric mouse strategies. The third aim is to investigate in vitro mechanisms whereby tubular CD36 modulates intracellular oxidation pathways during fibrosis. By improving our understanding of the key cellular receptors and the pathways they mediate in the progression of renal fibrosis, these studies will help to identify potential therapeutic targets for chronic kidney disease (CKD) with the goal of developing novel therapies to halt or slow the progression of CKD and alleviate the tremendous health burden of end-stage renal disease. This research will prepare the applicant for an academic career as an independent investigator in the field of kidney fibrogenesis. He will obtain further training in molecular biology, biological mass spectrometry analysis, develop in vitro model systems and gain expertise in the field of renal fibrosis. The transition to independence will be facilitated by the rich environment provided under the mentorship of Dr. Allison Eddy and collaborations with Drs. Jay Heinecke and Maria Febbraio, and by joining a large community of productive researchers focusing on the pathobiology of renal disease at the University of Washington.
描述(由申请人提供):

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

DARYL Miyoshi OKAMURA其他文献

DARYL Miyoshi OKAMURA的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('DARYL Miyoshi OKAMURA', 18)}}的其他基金

Uncovering CD36-mediated oxidative and inflammatory pathways in progressive renal
揭示进行性肾病中 CD36 介导的氧化和炎症途径
  • 批准号:
    7638229
  • 财政年份:
    2009
  • 资助金额:
    $ 12.83万
  • 项目类别:
Uncovering CD36-mediated oxidative and inflammatory pathways in progressive renal
揭示进行性肾病中 CD36 介导的氧化和炎症途径
  • 批准号:
    7919307
  • 财政年份:
    2009
  • 资助金额:
    $ 12.83万
  • 项目类别:
Multifunctional role CD36 in progressive renal fibrosis
CD36在进行性肾纤维化中的多功能作用
  • 批准号:
    7637999
  • 财政年份:
    2006
  • 资助金额:
    $ 12.83万
  • 项目类别:
Multifunctional role CD36 in progressive renal fibrosis
CD36在进行性肾纤维化中的多功能作用
  • 批准号:
    7446765
  • 财政年份:
    2006
  • 资助金额:
    $ 12.83万
  • 项目类别:
Multifunctional role CD36 in progressive renal fibrosis
CD36在进行性肾纤维化中的多功能作用
  • 批准号:
    7255782
  • 财政年份:
    2006
  • 资助金额:
    $ 12.83万
  • 项目类别:

相似海外基金

Deconstructing the diet-induced remodeling of adipose tissue
解构饮食诱导的脂肪组织重塑
  • 批准号:
    10567053
  • 财政年份:
    2023
  • 资助金额:
    $ 12.83万
  • 项目类别:
Histologic and Transcriptional Profiling of Endothelial Cells During Progressive Pulmonary Fibrosis
进行性肺纤维化期间内皮细胞的组织学和转录谱
  • 批准号:
    10616601
  • 财政年份:
    2022
  • 资助金额:
    $ 12.83万
  • 项目类别:
Histologic and Transcriptional Profiling of Endothelial Cells During Progressive Pulmonary Fibrosis
进行性肺纤维化期间内皮细胞的组织学和转录谱
  • 批准号:
    10419046
  • 财政年份:
    2022
  • 资助金额:
    $ 12.83万
  • 项目类别:
Small molecule antagonists targeting EphB receptors for the treatment of nonalcoholic steatohepatitis (NASH)
靶向 EphB 受体的小分子拮抗剂用于治疗非酒精性脂肪性肝炎 (NASH)
  • 批准号:
    10618311
  • 财政年份:
    2021
  • 资助金额:
    $ 12.83万
  • 项目类别:
Small molecule antagonists targeting EphB receptors for the treatment of nonalcoholic steatohepatitis (NASH)
靶向 EphB 受体的小分子拮抗剂用于治疗非酒精性脂肪性肝炎 (NASH)
  • 批准号:
    10216710
  • 财政年份:
    2021
  • 资助金额:
    $ 12.83万
  • 项目类别:
Small molecule antagonists targeting EphB receptors for the treatment of nonalcoholic steatohepatitis (NASH)
靶向 EphB 受体的小分子拮抗剂用于治疗非酒精性脂肪性肝炎 (NASH)
  • 批准号:
    10455535
  • 财政年份:
    2021
  • 资助金额:
    $ 12.83万
  • 项目类别:
EphB/EphrinB signaling in Systemic Sclerosis
系统性硬化症中的 EphB/EphrinB 信号传导
  • 批准号:
    10697360
  • 财政年份:
    2020
  • 资助金额:
    $ 12.83万
  • 项目类别:
EphB/EphrinB signaling in Systemic Sclerosis
系统性硬化症中的 EphB/EphrinB 信号传导
  • 批准号:
    10260572
  • 财政年份:
    2020
  • 资助金额:
    $ 12.83万
  • 项目类别:
Healthy Remodeling of Obese Adipose Tissue
肥胖脂肪组织的健康重塑
  • 批准号:
    9896820
  • 财政年份:
    2018
  • 资助金额:
    $ 12.83万
  • 项目类别:
EphB2 receptor tyrosine kinase in liver fibrosis
EphB2受体酪氨酸激酶在肝纤维化中的作用
  • 批准号:
    9766288
  • 财政年份:
    2018
  • 资助金额:
    $ 12.83万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了